New LaunchJul 16, 2026, 08:01 AM
Dyadic Expands Bio-Industrial Pipeline with New Enzyme Program
AI Summary
Dyadic International, Inc. announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program. This program focuses on advanced cellulose processing and utilizes the Company's Dapibus™ platform, building on the success of EN3ZYME™. The new enzyme is designed for applications such as pulp biorefining and nanocellulose production, targeting the multi-billion-dollar global industrial enzyme market. Dyadic plans diverse commercialization pathways, including direct sales, partnerships, and licensing.
Key Highlights
- Launched a new proprietary industrial enzyme program focused on advanced cellulose processing.
- Program leverages the Dapibus™ platform, demonstrating repeatable product development capabilities.
- New enzyme designed for applications like pulp biorefining, microcrystalline, and nanocellulose production.
- Targets the multi-billion-dollar global industrial enzyme sector.
- Commercialization pathways include direct sales, collaborations, contract manufacturing, and licensing.
- Follows the successful commercialization of Dyadic's first proprietary enzyme, EN3ZYME™.
Price Impact
More from DYAI